The authors present results of studying the effectiveness of a new class of medicines--preparations of the group "Glutoxim" (Molixan, Redoxell, Bikvolit, Liglutin) obtained on the model of experimental cirrhosis of the liver in 76 white rats caused by dimethylnitrosamin, and describe their first experience with using thiopoietins in 24 patients with cirrhosis of the liver in a surgical clinic. It was found that three weeks of treatment with Molixan and Bikvolit gave a significant hepatoprotecting effect (less amount of the connective tissue, reduction of the dystrophic processes in hepatocytes). A positive effect of Redoxell was shown in longer time of treatment. When used in clinic therapy with thiopoietins was followed by correction of the T-cell link of immunity in most patients. One of the most important results of treatment with medicines of the group of thiopoietins was a substantial improvement of the quality of life of the patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Reaching Syrian migrants through Dutch municipal registries for hepatitis B and C point-of-care testing.
PLoS One
January 2025
Department of Sexual Health, Infectious Diseases and Environmental Health, Living Lab Public Health, South Limburg Public Health Service, Heerlen, The Netherlands.
Undetected chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections can lead to cirrhosis and liver cancer. Syrian migrants are the largest non-European migrant group in the Netherlands with HBV and HCV prevalence rates above 2%. This study aimed to reach Syrian migrants for HBV and HCV testing using point-of-care tests (POCT).
View Article and Find Full Text PDFSafety and Outcomes of an On-Demand Transfusion Strategy Versus Prophylactic Transfusion of Platelets in Patients With Liver Cirrhosis and Severe Thrombocytopenia Undergoing High-Risk Procedures: A Analysis of Two Randomized Controlled Trials.
J Clin Exp Hepatol
November 2024
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India.
Background: There are limited studies assessing whether prophylactic platelet transfusions prior to high-risk procedures reduce the risk of bleeding in patients with liver cirrhosis.
Methods: We performed a analysis of two prior randomized clinical trials (CTRI/2017/12/010822 and CTRI/2021/05/033464), which compared thromboelastography-guided prophylactic platelet transfusion to standard-of-care (empirical prophylactic transfusion for all patients prior to the procedure) or on-demand transfusion (no prophylactic transfusions). We aimed to assess the risk of major procedure-related bleeding or mortality among patients who had received prophylactic platelet transfusions versus those who did not (on-demand transfusions).
Migration of Hepatocellular Carcinoma Into the Right Atrium.
JACC Case Rep
December 2024
Division of Cardiology, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
A 40-year-old man with a medical history of hepatitis B presented with abdominal distention and leg swelling. A computed tomography scan of the abdomen revealed cirrhosis and a large mass extending from the liver into the inferior vena cava and extending into the right atrium. A transthoracic echocardiogram revealed a large right atrial mass extending from the inferior vena cava with possible attachment to the interatrial septum.
View Article and Find Full Text PDFOutcomes of Coronary Artery Bypass Grafting (CABG) Patients With and Without a History of Liver Transplant.
Cureus
December 2024
Gastroenterology, Northwell Health, Bay Shore, USA.
Background: Liver transplant (LT) patients face various challenges, including an increased risk of coronary artery disease (CAD) for a variety of reasons, with 70% of LT recipients having one cardiovascular event. Coronary artery bypass grafting (CABG) remains one of the most commonly performed major surgical procedures in the United States, with 20-30% of LT patients requiring a CABG. Many studies have analyzed when to perform a CABG and CAD workup pre-LT, but this population remains a problem.
View Article and Find Full Text PDFDAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
J Viral Hepat
February 2025
Clinica Universidad de Navarra, Pamplona, Spain.
Direct-acting antiviral (DAA) therapy is associated with a significant reduction in hepatocellular carcinoma (HCC) incidence among patients with cirrhosis, but data are conflicting about the risk of recurrence following DAA therapy. DAA-PASS was a prospective, pragmatic, observational study designed to estimate the risk of HCC recurrence associated with DAA therapy exposure during routine clinical care. Eligible patients were DAA treatment naive with Barcelona Clinic Liver Cancer (BCLC) stage A.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!